Description: Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Home Page: www.genscript.com
Jiangning Science Park
Nanjing,
211100
China
Phone:
86 25 5889 7288
Officers
| Name | Title |
|---|---|
| Mr. Jiange Meng | Chairman |
| Dr. Zhenyu Liu | Chief Exec. Officer |
| Ms. Ye Wang M.S. | Co-Founder, Pres & Exec. Director |
| Mr. Shiniu Wei | Chief Financial Officer |
| Ms. Weihui Shao | Chief Operating Officer |
| Dr. Li Zhu Ph.D. | Chief Strategy Officer & Exec. Director |
| Dr. Chuan-Chu Chou | Head of Discovery and Preclinical Services |
| Mr. Chifa Zhang | Department Head of Industry Synthetic Biology Product Segment |
| Dr. Brian Hosung Min | CEO of Biologics Bus. |
| Ms. Wai Ling Wong A.C.I.S., A.C.S., ACIS, ACS | Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 96.1538 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.1146 |
| Price-to-Sales TTM: | 82.0838 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5573 |